| Trial ID: | L2578 |
| Source ID: | NCT04641312
|
| Associated Drug: |
Ly3457263
|
| Title: |
A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Healthy|Type 2 Diabetes
|
| Interventions: |
DRUG: LY3457263|DRUG: Dulaglutide|DRUG: Placebo
|
| Outcome Measures: |
Primary: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module, Baseline through Day 42 | Secondary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3457263, PK: AUC\[0-inf\] of LY3457263, Day 1 through Day 42
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
67
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2020-11-25
|
| Completion Date: |
2021-12-21
|
| Results First Posted: |
|
| Last Update Posted: |
2022-01-11
|
| Locations: |
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, 41460, Germany|Profil Mainz, Mainz, 55116, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT04641312
|
